A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Mirati Therapeutics, Inc.
Start Date
July 9, 2019
End Date
August 5, 2024
Administered By
Duke Cancer Institute
Awarded By
Mirati Therapeutics, Inc.
Start Date
July 9, 2019
End Date
August 5, 2024